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Abstract
Primary Familial Brain Calcification (PFBC), a neurodegenerative disease characterized by
progressive pericapillary calcifications, has recently been linked to heterozygous mutations
in PDGFB and PDGFRB genes. Here, we functionally analyzed several of these mutations
in vitro. All six analyzed PDGFBmutations led to complete loss of PDGF-B function either
through abolished protein synthesis or through defective binding and/or stimulation of
PDGF-Rβ. The three analyzed PDGFRBmutations had more diverse consequences.
Whereas PDGF-Rβ autophosphorylation was almost totally abolished in the PDGFRB
L658P mutation, the two sporadic PDGFRBmutations R987W and E1071V caused reduc-
tions in protein levels and specific changes in the intensity and kinetics of PLCγ activation,
respectively. Since at least some of the PDGFBmutations were predicted to act through
haploinsufficiency, we explored the consequences of reduced Pdgfb or Pdgfrb transcript
and protein levels in mice. Heterozygous Pdgfb or Pdgfrb knockouts, as well as double
Pdgfb+/-;Pdgfrb+/- mice did not develop brain calcification, nor did Pdgfrbredeye/redeyemice,
which show a 90% reduction of PDGFRβ protein levels. In contrast, Pdgfbret/retmice, which
have altered tissue distribution of PDGF-B protein due to loss of a proteoglycan binding
motif, developed brain calcifications. We also determined pericyte coverage in calcification-
prone and non-calcification-prone brain regions in Pdgfbret/retmice. Surprisingly and con-
trary to our hypothesis, we found that the calcification-prone brain regions in Pdgfbret/ret
mice model had a higher pericyte coverage and a more intact blood-brain barrier (BBB)
compared to non-calcification-prone brain regions. While our findings provide clear evi-
dence that loss-of-function mutations in PDGFB or PDGFRB cause PFBC, they also
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demonstrate species differences in the threshold levels of PDGF-B/PDGF-Rβ signaling that
protect against small-vessel calcification in the brain. They further implicate region-specific
susceptibility factor(s) in PFBC pathogenesis that are distinct from pericyte and BBB
deficiency.
Introduction
The role of the platelet-derived growth factors (PDGFs) and their tyrosine kinase receptors
(PDGFRs) has been extensively studied in the developing organism [1,2]. Of the two prototypi-
cal PDGFRs, PDGF-Rα and PDGF-Rβ, the latter has been especially implicated in blood vessel
formation and early hematopoiesis. PDGF-Rβ signaling, initiated by the secretion of PDGF-B
ligand by endothelial cells, is paramount for the recruitment of PDGF-Rβ positive vascular
smooth muscle cells and pericytes during angiogenesis [3,4]. In mice, homozygous knockouts
of either receptor or ligand display widespread vascular alterations leading to perinatal death
[1,5,6]. Heterozygous knockouts, on the contrary, bear no or subtle phenotypic changes [7,8].
In comparison, the pathogenic roles of PDGFs are still poorly understood. Regarding
PDGF-B, increased PDGF-Rβ signaling has been demonstrated in diseases like cancer, vascular
inflammation, and tissue fibrosis [1]. Focal uncontrolled PDGF-Rβ signaling due to somatic
genetic aberrations has severe consequences in humans, playing a causative role in diseases
such as dermatofibrosarcoma protuberans [9], gastric cancer and leukemia [10]. Recently,
infantile myofibromatosis (IMF), a disease characterized by proliferative fibrous tumors during
childhood, was linked to putative gain-of-function germ-line mutations in PDGFRB [11–13].
The simultaneous discovery that mutations in PDGFB and PDGFRB can also cause primary
familial brain calcification (PFBC) demonstrates new functions of PDGF-Rβ signaling that
could not have been predicted based on existing knowledge about PDGF-B/ PDGF-Rβ func-
tions, demonstrating that there is still much to be learnt about PDGF biology [14,15].
PFBC, previously referred to as Fahr’s disease or idiopathic basal ganglia calcification
(IBGC), is a neurological disease characterized by age-dependent perivascular calcifications in
the brain and clinically heterogeneous symptoms ranging from Parkinsonism to cognitive
impairment [16]. This rare disorder has an autosomal-dominant pattern of inheritance
[14,17]. The first PFGC mutation in either PDGFB or PDGFRB to be described was the L658P
(c.1973T>C) missense mutation in the protein kinase catalytic domain of PDGF-Rβ, which
segregated with the disease in a large family with 13 PFBC patients [14]. Following this finding,
two additional and potentially pathogenic mutations in the C-terminal domain of PDGFRB,
R987W (c.2959C>T), and E1071V (c.3212A>T), were found in sporadic cases [14,17]. Lately,
a R695C (c.2083C>T) mutation was described in a single patient from an autopsy series of
PFBC [18]. Further strengthening the link between PFBC and PDGF-B/ PDGF-Rβ signaling,
six different nonsense and missense mutations in the gene encoding PDGF-B were identified
in six PFBC families of different ancestry [15]. A seventh nonsense mutation was reported in a
sporadic PFBC case [19]. These mutations include two missense mutations in the initiation
and in the stop codons, M1? (c.3G>A) and 242Yext89 (c.726G>C), the latter resulting in a
89 amino acid extension; one L9R (c.26T>G) missense mutation in the signal peptide; and one
missense and three nonsense mutations in the sequence coding for the growth factor domain
(L119P (c.356T>C); Q145 (c.433C>T); Q147 (c.439C>T) and R149 (c.445C>T), respec-
tively) [15,19]. Recently, a heterozygous intragenic deletion in PDGFB involving exons 2–5 of
PDGFB was described in a sporadic PFBC patient [20]. Fig 1 provides an overview of all
PDGFB and PDGFRBmutations.
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The predicted deleterious consequences of the nonsense mutations identified in PDGFB
and the dual involvement of PDGFB and PDGFRB led to the assumption that all PFBC muta-
tions were loss-of-function [15]. Two recent reports showed that some of the PDGFRBmuta-
tions described in PFBC indeed cause defective receptor autophosphorylation, protein stability
and/or downstream signaling [18,21]. However, consequences of the PDGFBmutations found
in PFBC cases have previously not been analyzed. Interestingly, mice carrying hypomorphic
Pdgfb alleles where PDGF-B retention motif has been deleted (Pdgfbret/ret mice) develop brain
calcifications that show age-related expansion [15].
While there is a link between impairment of PDGF-B signaling and familial PFBC, it is
unclear what kind and extent of impairment that is required to trigger PFBC. Since defective
PDGFB signaling also leads to severely reduced pericyte counts and a dysfunctional blood-
brain barrier in the adult mouse brain, we previously hypothesized a causal relationship
between these defects and the observed brain calcifications. However, it remains possible that
Fig 1. Overview of PFBC-related PDGFB and PDGFRBmutations. (A) In-scale schematic representation of a PDGF-BB dimer with the location of the
known PFBC-associated mutations. Cysteine residues involved in interchain disulfide bonds are indicated in orange. The relative position of different
mutations is indicated by stars. The predicted protein extension due to the stop codon mutation is indicated by dashed boxes. (B) Location of the main point
mutations in PDGFB in the PDGF-BB:PDGF-Rβ complex. Ribbon diagram of two PDGF-Rβ proteins (in blue) in complex with dimeric PDGF-B (in grey). The
location of the 3 stop mutations Q145*, Q147* and R149* are indicated in red. The location of the L119Pmissense mutation is indicated in green. The image
was created from PDB 3MJG (Platelet-derived growth factor subunit B) using PyMOL (The PyMOLMolecular Graphics System, Version 1.2r3pre,
Schrödinger, LLC. http://pymol.sourceforge.net/faq.html). (C) Schematic representation of a PDGFRβ dimer with the location of the known PFBC-associated
mutations. Ig-like C2-type domains are indicated by oval shapes. The split tyrosine-kinase domain is indicated by dark grey boxes. Tyrosine
autophosphorylation sites Y751, Y771, 71009 and Y1021 assessed in the article are indicated in purple. ATP-binding sites are indicated in black, including
the K634 residue mutated in our kinase-dead negative control. The relative position of the mutations is indicated by stars.
doi:10.1371/journal.pone.0143407.g001
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the pericyte/BBB deficiencies and brain calcifications represent independent consequences of
impaired PDGF-B signaling. Whereas all human PDGFBmutations described to-date are dom-
inant, and at least some of them able to act through haploinsufficiency, the Pdgfbret/ret mouse
model of PFBC is clearly acting differently. We therefore characterized human PDGFB and
PDGFRBmutations in vitro. Using biochemical and cellular approaches, we analyzed the
effects of the point mutations in PDGFB on expression and secretion of PDGF-B, activation of
PDGF-Rβ, and actin reorganization in primary human pericytes. We confirmed and comple-
mented previous findings on the effects of L658P, R987W and E1071V mutations in PDGFRB
by assessing receptor tyrosine kinase autophosphorylation, activation of downstream signal
transduction cascades and cell migration. Moreover, we analyzed the consequences of different
degrees of Pdgfb and/or Pdgfrb genetic insufficiency on pericyte coverage and blood-brain bar-
rier integrity in mice.
Results
PDGFBmutations are null or loss-of-function mutations
To study the functional consequences of PDGFBmutations described in PFBC (Fig 1A and
1B), cDNA sequences carrying the different mutations identified in six PFBC families were
introduced into the pcDNA3.1 vector, transfected into human embryonic kidney (HEK) 293
cells, and after G-418 selection, stably expressing clones were generated. Wild-type PDGFB
cDNA and empty pcDNA3.1 vector served as positive and negative controls, respectively. In
order to assess the expression and secretion of mutant PDGF-B, transfected cells were lysed for
RNA or protein extraction. In separated experiments, serum-free conditioned medium was col-
lected and analyzed.
All PDGFB constructs produced comparable levels of PDGFBmRNA in HEK293 cells (Fig
2A). To assess protein expression, a polyclonal anti-PGDF-B antibody was used inWestern blot-
ting of cell lysates. Wild-type PDGF-B was detected as a major14-kDa and a minor 25-kDa
species probably representing fully and partially proteolytically processed PDGF-B chains,
respectively (Fig 2B, arrowheads) [22]. Among the expression vectors expressing mutated
PDGF-B, PDGF-B antibodies detected specific PDGF-B products only from the initiation and
stop codon mutants, respectively (M1? and 242Yext89). The21–22 kDa PDGF-B protein in
M1?-transfected cells (Fig 2B, arrow in second lane) might be explained by an alternative transla-
tional start site. Of the several in-frame ATG codons that occur up- and downstream of the
native ATG, the M32 in the PDGF-B precursor would generate a 158 amino acid-long product
with a MW of21.5 kDa (if no further N-terminal or C-terminal processing occurs). The30
kDa-protein generated by the 242Yext89 mutation (Fig 2B, arrow in eighth lane), has a size
that would be predicted from an 89 residue-long C-terminal extension of a precursor protein in
which N-terminal processing occurred normally (Figs 2B and 1A). Since the PDGF-B precursor
protein is known to be differentially processed depending on whether it is routed for secretion or
degradation [22], we did not address the structure of the intracellular mutant PDGF-B proteins
further, but instead focused on the presence of a secreted biologically active PDGF-B protein.
None of the other constructs produced any detectable PDGF-B protein (Fig 2B).
Using a PDGF-Rβ-binding based ELISA to measure PDGF-BB concentration in the condi-
tioned media, we found that only the stop codon mutation (242Yext89) yielded detectable
amounts of secreted PDGF-BB (2.05 ± 0.64 ng/ml), however at 50-fold lower levels than in wild-
type PDGFB-transfected HEKs (Fig 2C). To assess the ability of the stop codon mutant
(242Yext89) to activate PDGF-Rβ, and to rule out the presence of functional, yet undetected,
PDGF-BB in the supernatant frommutant-transfected HEKs, serum-starved human brain peri-
cytes (HBPs) were exposed to conditioned medium collected fromHEK cells expressing different
PDGFB and PDGFRBMutations in Primary Familial Brain Calcification
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PDGFBmutants. While recombinant PDGF-BB and conditioned medium from wild-type
PDGFB-transfected HEKs induced detectable PDGF-Rβ phosphorylation (Fig 2D first and last
lane, respectively), media from all PDGFB mutant-transfected, as well as the empty vector-trans-
fected, HEKs failed to induce tyrosine phosphorylation of PDGFRβ above background levels (Fig
Fig 2. PFBC PDGFBmutations result in loss of detectable and/or functional PDGF-BB. (A) qPCR analysis for human PDGFB in stably transfected
HEK293 cells. Individual vectors expressing each of the mutations identified in PFBC families were stably transfected into HEK cells. Wild-type (WT) PDGFB-
expressing construct and empty vector (pcDNA) were used as positive and negative controls, respectively. mRNA levels are shown as fold increase over
basal expression of PDGF-B in HEK cells. 18s Ribosomal RNA was used for normalization. Error bars indicate standard deviation of three independent
experiments. (B) Detection of PDGF-B protein expression in stably transfected HEK293 cells. Immunoblot of HEK293 cell lysates showing expression of the
different PDGFB constructs. The arrowheads indicate the 2 bands corresponding to PDGF-B in the wild-type condition, probably representing fully and
partially proteolytically processed PDGF-B chains. Arrows indicate specific bands migrating slower due to a mutation-induced size shift. Non-specific bands
in the background are marked with asterisks. (C) ELISA assay for detection of PDGF-BB in conditioned medium of stably transfected HEK cells. HEK cells
overexpressing the different PFBCmutations were serum-starved for 24 hours prior to collection of their growth medium. An ELISA specific for human
PDGF-BB was performed to detect secreted PDGF-BB. Error bars indicate the standard deviation over three individual measurements. ND: Not detected.
(D). Western blot of autophosphorylation of PDGF-Rβ in human brain pericytes (HBP). HBPs were serum-starved overnight, cooled on ice and their medium
replaced by either cooled conditioned medium from B-C, or cooled pericyte medium supplemented with 10 ng/ml PDGF-BB (right lane). After 1 hour-
incubation on ice, cells were lysed and immunoblots were performed on duplicate membranes using anti-phospho-PDGF-Rβ (Y771) and anti-total PDGF-Rβ
(28E1) antibodies.
doi:10.1371/journal.pone.0143407.g002
PDGFB and PDGFRBMutations in Primary Familial Brain Calcification
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2D lanes 2–8 and 9, respectively). Likewise, conditioned media from HEK cells expressing the
PFBC PDGFBmutations failed to induce rearrangement of the actin cytoskeleton (Fig 3D and S1
Fig). In marked contrast, conditioned medium from wild-type PDGFB-transfected HEKs, or
PDGF-BB at concentrations as low as 2 ng/ml, induced a profound reorganization of the actin
cytoskeleton in HBPs (Fig 3A and 3B). Actin remodeling anifested as a loss of stress fibers and
Fig 3. Conditionedmedium frommutant PDGFB-transfected HEK cells fails to inducemembrane
ruffles in human brain pericytes. After overnight serum starvation, human brain pericytes (HBP) were
cooled on ice and exposed to cooled conditioned medium from HEK cells (described in Fig 1B and 1C) for 15
minutes, then warmed up in at 37°C for 30 min and fixed for phalloidin staining. A low concentration of
exogenous PDGF-BB (2 ng/ml) in serum-free pericyte medium (A) and conditioned medium from wild-type
PDGFB-transfected HEKs (B) were used as a positive controls. Supernatant from pcDNA-transfected HEKs
was used as a negative control (C). The first two conditions induced widespread circular ruffles (arrowheads),
which were absent in the negative control. Likewise, HBP treated with conditioned medium frommutant
PDGFB transfected HEKs did not show any ruffles: (D) *242Yext*89 mutation, (E) M1? mutation and (F) L9R
mutation. Cyan: DAPI. Green: Alexa 488 conjugated phalloidin. Scale bar: 30 μm.
doi:10.1371/journal.pone.0143407.g003
PDGFB and PDGFRBMutations in Primary Familial Brain Calcification
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the formation of peripheral and circular ruffles, the latter being one of the earliest, most sensitive
and specific cellular events following PDGF-BB stimulation [23–25].
In conclusion, all six analyzed PDGFBmutations lead to a complete abolishment of a func-
tional PDGF-B protein when expressed in vitro individually and in the absence of wild-type
PDGF-B. Additionally, most of the mutations appeared to cause a complete loss of PDGF-B
protein production (i.e. nullmutations), suggesting that PDGFB haploinsufficiency could be a
sufficient cause of PFBC (overview in S1 Table).
The L658P mutation in PDGFRB abolishes PDGF-BB dependent
receptor autophosphorylation
To study the functional consequences of PDGFRBmutations, pcDNA3.1 constructs containing
3 different PDGFRBmutations identified in PFBC patients (L658P, R987W and E1071V, Fig
1C) were transfected into porcine aortic endothelial (PAE) cells. Additional transfections of
constructs encoding wild-type PDGF-Rβ, kinase-dead (KD) PDGF-Rβ (K634A) [26] and
empty expression vector served as positive and negative controls.
Stable transfection of PDGFRB constructs into PAE cells resulted in PDGFRBmRNA pro-
duction, while PDGFRBmRNA was undetectable in the empty vector control (Fig 4A). There
was no significant difference in PDGFRBmRNA levels between the different constructs, indi-
cating similar transfection and transcription efficiencies between expression vectors encoding
mutant or wild-type PDGFRB. The relative PDGF-Rβ protein expression level was assessed by
Western blotting. The KD and R987W PDGF-Rβmutants yielded a significantly weaker signal
(40 and 15%, respectively) as compared with wild-type PDGF-Rβ, whereas the expression level
of L658P and E1071V PDGF-Rβmutants did not differ from wild-type PDGF-Rβ. Proteasome
and lysosome inhibitors (MG-132 and chloroquine, respectively) did not significantly increase
the amount of PDGF-Rβ R987W protein, suggesting that the lower protein level was not due to
increased turnover of the protein (Fig 4B).
Upon ligand binding, PDGF-Rβ dimerizes and autophosphorylates on as many as 13 cyto-
plasmic tyrosine residues [1,27]. We assessed four of these (Y751, Y771, Y1009 and Y1021).
PDGF-BB treatment of wild-type PDGFRB-transfected cells induced a strong phosphorylation
of PDGF-Rβ in all four tested tyrosine residues. Conversely, there was no detectable phosphor-
ylation of KD PDGF-Rβ, despite a total PDGF-Rβ protein signal was equivalent to the wild-
type condition (Fig 4C and 4D and S2 Fig). Assessment of PFBC PDGF-Rβmutants showed
that similar to the KD condition, the L658P mutant displayed a nearly complete abolition of
the phospho-PDGF-Rβ signal following PDGF-BB treatment in all tested tyrosine residues. In
contrast, the R987W and E1071V mutants behaved like wild-type PDGF-Rβ with regard to
phosphorylated/total protein ratio in the PDGF-BB-treated condition (Fig 4C and 4D).
Detailed analysis of each tyrosine residue yielded the same results, with the exception of slightly
weaker Y1009 and Y1021 phosphotyrosine signals in the R987Wmutant (S2 Fig).
Downstream signaling is compromised by PDGFRB L658P mutation
and, to a lesser extent, by R987W and E1071V mutation
Within minutes of PDGF-Rβ autophosphorylation, many intracellular signaling pathways are
engaged. These include Ras-MAPK, PI3K/Akt and PLCγ [1,27,28]. As expected, phosphoryla-
tion of ERK1/2 and Akt was reduced or absent in the cells expressing the L658P mutant after
PDGF-BB stimulation (Fig 5A). The R987W PDGF-Rβmutation showed lower ERK1/2 and
Akt activation at 5 minutes after ligand stimulation. More strikingly, PLCγ activation was
markedly decreased at all time points in cells expressing the R987W and E1071V mutants
expressing cells after PDGF-BB exposure as compared to wild-type PDGF-Rβ (Fig 5A and 5B).
PDGFB and PDGFRBMutations in Primary Familial Brain Calcification
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Fig 4. Expression and autophosphorylation of PDGF-Rβmutants in PAE cells. PAE cells were stably transfected with vectors expressing the different
PFBCmutations found in PDGFRB. (A) After mRNA extraction, the total expression of human PDGFRBwas detected with qPCR. Error bars indicate
standard deviation between 3 independent experiments. ND: Not detected. (B) Immunoblot demonstrating the protein expression levels of the different
PDGFRBmutants. Stable clones of mutant PDGFRB expressing PAE cells were treated with a proteasomal inhibitor (MG-132), lysosomal inhibitor
(chloroquine) or vehicle for 4 hours before lysis. Total levels of PDGF-Rβ were visualized with anti-total PDGF-Rβ (28E1) antibody. The graphs indicate
relative expression level of the inhibitor-treated conditions vs control condition for three individual experiments. Error bars indicate standard deviation.
*p<0.05 compared to basal wild type (WT) expression, #p<0.05 when comparing inhibitor-treated vs control condition for each mutant. (CD)
Autophosphorylation of the PDGF-Rβmutants. PAE cells stably expressing mutant PDGF-Rβwere exposed to 40 ng/ml of exogenous PDGF-BB for 60
minutes after cooling on ice. A wild-type PDGFRB-expressing construct was used as a positive control, while a kinase dead (KD) variant was used as a
negative control. Cell lysates were adjusted to yield a comparable amount of PDGF-Rβ signal. (C) Representative western blot demonstrating
autophosphorylation of the different mutants on four residues. (D) Quantification of PDGF-Rβ autophosphorylation signal from tyrosine residues 751, 771,
1009 and 1021 using phospho-specific antibodies. Signals were normalized over total levels of PDGF-Rβ protein, and expressed as a percentage of wild-
type PDGF-Rβ autophosphorylation. The graph represents the averaged results from the 4 tyrosine residues that were assessed in three independent
experiments. *p<0,05 when compared to the positive control (WT PDGF-Rβ).
doi:10.1371/journal.pone.0143407.g004
PDGFB and PDGFRBMutations in Primary Familial Brain Calcification
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To elucidate the influence of the PDGF-Rβmutations on PAE cell behavior, we investigated
the ability of these cells to form membrane ruffles when treated with PDGF-BB. Although PAE
cells expressing wild-type, or R987W or E1071V-mutated PDGF-Rβ all displayed membrane
ruffles after PDGF-BB stimulation, the number of ruffles were slightly but significantly lower
in cells expressing R987W or E1071V mutants. In contrast, membrane ruffles were rare in
PDGF-BB treated PAE cells expressing the L658P mutant or in empty vector transfected con-
trol cells (Fig 6A and 6B).
Since membrane protrusions are known to play a role in cell migration, we investigated if
the compromised inability of the PAE cells to form membrane ruffles correlated with any
impairment in cell migratory potential. Whereas wild-type PDGFRB-transfected cells grown to
confluency did close a ~730 μm-wide scratch wound to completion (100%) in 13 hours upon
serum starvation followed by PDGF-BB stimulation, the relative wound closure was less than
40% for empty vector and KD PDGFRB-transfected cells (Fig 6D) with no significant effect
over background of PDGF-BB stimulation (Fig 6C). Cells transfected with vector encoding
PDGF-Rβ L658P behaved similar to cells transfected with empty vector or vector encoding KD
PDGF-Rβ. Interestingly, cells expressing R987W and E1071V PDGF-Rβmutants did not show
differences from cells expressing wild-type PDGF-Rβ in scratch wound assay (Fig 6C and 6D
and S1 Movie).
Overall, of all the analyzed PDGFRBmutations, only the L658P mutation behaved as a com-
plete loss-of-function mutation. R987W and E1071V mutants retained significant biological
activity in different cell assays. However, R987Wmutation caused lower protein synthesis and/
Fig 5. Effect of PDGFRBmutations on PDGF-B signaling. (A) Western blot for known downstream targets of PDGF-B signaling. PAE cells were
stimulated with 40 ng/ml PDGF-BB for the indicated time periods. Autophosphorylation of PDGF-Rβmutants was investigated with a phosphospecific
antibody raised against tyrosine 771, while downstream PDGF-BB signaling was assessed with antibodies directed against phosphorylated activated forms
of ERK 1/2, Akt and PLCγ. β-actin was used as a loading control. (B). To quantify ERK 1/2, Akt and PLCγ activations over time, the signals were normalized
over β-actin levels and plotted against time. Error bars indicate the standard deviation of three independent experiments. *p˂0,05 when compared to wild-
type PDGFRβ (red), with the color of the star indicating the mutant PDGFRβ that is being compared to wild-type PDGFRβ (blue: L658P, yellow: R987W,
brown: E1071V).
doi:10.1371/journal.pone.0143407.g005
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Fig 6. Effect of PDGFRBmutations onmembrane ruffle formation and wound healing. (AB)
PDGF-BB—induced membrane ruffling of stably transfected PAE cells expressing mutant PDGF-Rβ
receptor. (A) Fluorescent labeling of the actin cytoskeleton in PAE cells after 30 minutes of PDGF-BB
exposure. Arrowheads indicate peripheral membrane ruffles. Cyan: DAPI, green: Alexa 488-conjugated
phalloidin. Error bar: 30 μm. (B) The total amount of ruffles was counted in 20 fields per condition, and
normalized over the total amount of cells. *p˂0.05 as compared to wild-type PDGFRB-expressing PAE
cells. Empty vector (pcDNA) and KD PDGFRB-transfected cells were used as negative controls. (CD)
Wound healing assays of stably transfected PAE cells expressing different mutant PDGFRβ receptors.
Confluent monolayers of PAE cells expressing different PDGFRB constructs were scratched using the
WoundMaker™ and wound closure was monitored automatically every hour for 13 hours with the
IncuCyte Zoom1. (C) Representative images of the wound at 0 and 13 hours of PDGF-BB stimulation.
(D) Quantification of the increase in relative wound density within 13 hours. Error bars indicate standard
deviation between 6 individual scratches, 2 images per scratch.
doi:10.1371/journal.pone.0143407.g006
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or decreased stability of the receptor, whereas the E1071V mutant exerted a limited negative
effect on PDGFRβ downstream signaling (overview in S1 Table).
Genetic haploinsufficiency for Pdgfb and/or Pdgfrb or a substantial
decrease in PDGF-Rβ protein do not trigger brain calcification in mice
Whereas most of the PDGFBmutations in PFBC lead to complete loss of PDGF-B protein syn-
thesizing capacity from the mutant PDGFB allele, the mode(s) of inactivation of PDGF-Rβ
encoded by the PDGFRBmutations remains unclear. Since the mutant PDGF-Rβ proteins are
expressed, they may, in principle, work as dominant-negative proteins. Assuming that only
PDGF-Rβ dimers consisting of two wild-type subunits have the capacity to signal, a dominant-
negative mutant would reduce total signaling strength by a maximum of 75% [29]. We have
previously reported that two transgenic Pdgfb hypomorphs: Pdgfbret/ret and Pdgfb−/−;R26P+/0
mice form age-dependent pericapillary nodules that progressively get calcified [15]. While
these mice constitute mouse models of PFBC, we suspected that the degree of PDGF-B signal-
ing impairment in those models exceeds the one in human PFBC.
In order to more closely mimic the degree of loss of PDGF-Rβ signaling deduced from our
analysis of the mutant human PDGF-B and PDGF-Rβ proteins, we investigated other mouse
models of Pdgfb and/or Pdgfrb hypomorphism. We first bred mice heterozygous null for Pdgfb
and Pdgfrb (Pdgfb+/-;Pdgfrb+/-) and allowed them to age. This situation combines the features
of the PDGFB haploinsufficiency observed with most PDGFBmutations with the decreased
PDGF-Rβ expression seen in the R987Wmutant. The combined loss of 50% of PDGF-B and
50% of PDGF-Rβ would also be predicted to lead to a 75% total reduction of PDGF-Rβ signal-
ing strength, thereby mimicking a putative dominant-negative PDGF-Rβmutant. Doubly het-
erozygous mice null for Pdgfb and Pdgfrb (Pdgfb+/-;Pdgfrb+/-) were viable and did not display
any overt phenotype. The brain mRNA levels of Pdgfb and Pdgfrb were near half of those in
wild-type, suggesting little or no compensation of the haploinsufficiency at the mRNA level
(Fig 7A). Whereas Pdgfbret/ret mice display calcified nodules as early as 4 months after birth,
which progressed in size and number with age, as previously reported [15], Pdgfb+/-;Pdgfrb+/-
mice did not display any signs of brain calcification by Von Kossa staining (data not shown) or
micro-CT brain scans (Fig 7C), even at advanced age (12–14 months) when such lesions are
prevalent in Pdgfbret/ret mice (Fig 7C).
To further lower the gene dose of Pdgfrb, we took benefit of the recently described redeye
mouse mutant [30]. This mouse strain carries a Pdgfrbmutation at position +2 of intron 6, caus-
ing partial loss of normal splicing. Retaining intron 6 results in a frame shift and premature ter-
mination of the protein, which results in an estimated 75% reduction in the amount of Pdgfrb
mRNA in homozygous mice [30]. Pdgfrbredeye/redeye, Pdgfrbredeye/+ and wild-type mice were bred
and analyzed at 6 months. Western blot for PDGF-Rβ performed on brain lysates demonstrated
an even more dramatic decrease in protein signal than reported [30], reaching only 10% of the
wild-type levels in Pdgfrbredeye/redeyemice (Fig 7B). Similarly to Pdgfb+/-;Pdgfrb+/- mice, we did not
detect vessel-associated calcifications in Pdgfrbredeye/redeyemice using various histostains (data not
shown) or by micro-CT scans (Fig 7C). Thus, in mice, haploinsuffiency for Pdgfb and Pdgfrb, as
well as a substantial decrease in PDGF-Rβ protein levels caused by a splicing mutant, were insuf-
ficient to cause a PFBC-like pathology.
The vascular calcification process does not correlate with pericyte loss
and blood-brain barrier dysfunction
Since our previous analysis established a correlation between brain calcifications and the loss
of pericytes in Pdgfbret/ret and Pdgfb−/−;R26P+/0 mice, we next assessed the pericyte coverage of
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the small vessels in Pdgfb+/-;Pdgfrb+/- and Pdgfrbredeye/redeye mice, in search for age-dependent
pre-calcification changes. Pdgfb+/-;Pdgfrb+/- mice displayed a modest 20–30% decrease in peri-
cyte coverage (Fig 8A and 8B), that either worsened with ageing (29±15% decrease at 6 months
and 20±9% decrease at 12–14 months) nor varied according to anatomical location (13±1%
decrease in the dorsal pons, a calcification prone region in Pdgfbret/ret mice, as compared with
19±11% decrease in the cortex, a calcification-non-prone region in Pdgfbret/ret mice) (Fig 8B).
Pdgfrbredeye/redeye, Pdgfrbredeye/+ and wild-type mice did not display any significant decrease in
pericyte coverage in the dorsal pons and in the cortex (Fig 8C).
As Pdgfbret/ret and Pdgfb−/−;R26P+/0 mice also display an impaired blood-brain barrier the
degree of which correlates with brain calcification, we investigated passage of exogenous tracer
cadaverine-Alexa 555 from the blood into the brain. In Pdgfb+/-;Pdgfrb+/- (Fig 8D), as well as in
Pdgfrbredeye/redeye mice (Fig 8E), the blood-brain barrier permeability to the tracer was similar
to controls.
Pdgfbret/ret mice invariably develop calcifications in specific brain regions (thalamus, pons,
mesencephalon, basal forebrain) from 4 months of age while displaying a general reduction in
Fig 7. Screening for calcifications in Pdgfb+/-; Pdgfrb+/- and Pdgfrbredeye/redeyemice. (A). RT-PCR for murine Pdgfb and Pdgfrb in brain total RNA
extractions. mRNA levels of Pdgfb and Pdgfrb are shown relative to the expression in wild-type animals. *p<0.05 as compared to wild-type animals. Error
bars indicate standard deviation of mRNA levels in 4 different animals. (B). Western Blot for PDGFRβ levels in Pdgfrbredeye/redeye mice. A representative
Western blot indicates the reduction in detectable protein level of PDGFRβ in two mice for each genotype. As a loading control, β-actin was used. The graphs
display a quantification of the levels of PDGFRβ. Error bars indicate standard deviation of receptor levels from 4 animals each. *p<0.05 as compared to wild-
type animals. (C). Micro computed tomography (micro-Ct) analysis of Pdgfbret/ret, Pdgfb+/-;Pdgfrb+/- and Pdgfrredeye/redeyemouse brains. After perfusion, the
mouse brain of aged mice was surgically removed and prepared for micro-Ct. For each genotype, three brains were scanned. Brains of Pdgfbret/retmice were
used as a positive control, and Pdgfbret/+, Pdgfrbredeye/+ or wild-type mice were used as negative controls.
doi:10.1371/journal.pone.0143407.g007
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Fig 8. Assessment of vessel pericyte coverage and blood-brain barrier integrity in aged Pdgfrbredeye/redeye and Pdgfb+/-; Pdgfrb+/-mice. (ABC)
Assessment of pericyte coverage. A CD13 and CD31 co-immunolabelling was performed on 50 μm-thick parasagittal vibratome sections. (A) Representative
2D projections of ~40 μm z-stacks taken from the dorsal pons of wild-type (left panels) and double heterozygous (right panels) animals; upper panels (red):
CD13 immunostaining; lower panels: merged CD31 (green) and CD13 immunostainings. Inserts provide a more detailed indication of the coverage rate.
Scale bar: 30 μm. The capillary surface coverage rate in Pdgfb+/-; Pdgfrb+/- (B) and Pdgfrbredeye/redeyemice (C) was calculated and is plotted as the
percentage of the vessel surface enveloped by pericytes. Two pictures from the dorsal pons and two pictures from the cortex were analyzed for each animal.
The standard deviation of pericyte coverage of 4 animals per genotype is indicated by the error bars. WTmice and heterozygous Pdgfrbredeye/redeyemice
were used as controls. (DE) Blood-brain barrier permeability assessment in Pdgfb+/-; Pdgfrb+/- (D) and Pdgfrbredeye/redeye (E) mice. Lysine-fixable cadaverine
conjugated to Alexa Fluor-555 was injected intravenously into the tail vein (5 mg/ml in saline) 2 hours before sacrifice. Fluorescence was measured in the
brain homogenate and arbitrary fluorescence units (AFU) were normalized to the brain weight. Error bars indicate standard deviation of fluorescence level
measurement in 4 different animals. (F). Pericyte coverage of vessels in calcification prone regions compared with non-calcification-prone regions. Different
brain regions were assessed for pericyte coverage in Pdgfbret/ret mice and the result is plotted as the percentage of the vessel surface enveloped by
pericytes. For each animal, two pictures from the dorsal pons (calcification-prone) and two pictures from the cortex (non-calcification-prone) were analyzed.
The standard deviation of pericyte coverage of 4 animals per genotype is indicated by the error bars. *p<0,05 when comparing Pdgfbret/ret with Pdgfbret/+,
#p<0,05 when comparing calcification-prone regions with non-calcification-prone regions in Pdgfbret/ret mice. (G). Analysis of blood-brain barrier integrity in
calcification prone regions compared to non-calcification-prone regions. Alexa Fluor-555 conjugated cadaverine tracer was allowed to circulate for 2 hours
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pericyte coverage of brain capillaries and increased permeability of the blood-brain barrier. In
contrast, Pdgfb+/-;Pdgfrb+/- mice presented only a minor decrease in vessel pericyte coverage
and no vessel-associated calcification. These data strengthen the previously observed correla-
tion [15] between the degree of overall brain pericyte loss and BBB impairment and the forma-
tion of brain calcification. However, certain brain regions (e.g. cerebral cortex) with severe
pericyte loss and BBB deficiency did not develop brain calcifications. Therefore, we further
investigated the spatial relationship between pericyte coverage, blood-brain barrier permeabil-
ity and the formation of calcified nodules in Pdgfbret/ret mice. Surprisingly, we found that the
pericyte coverage was significantly higher in the 3 calcification-prone regions (thalamus, mes-
encephalon and dorsal pons; 13±3%) compared to 3 calcification-non-prone regions (motor
cortex, hippocampus and myelencephalon; 6±2%) (Fig 8F and S3 Fig). Likewise, BBB perme-
ability was increased 2 to 6-fold as compared with Pdgfbret/+ mice in all brain regions, but the
vasculature in calcification-prone regions was significantly less permeable than in calcification-
non-prone regions (Fig 8G and S3 Fig), mostly because of the high BBB permeability of telence-
phalic structures (cortex, hippocampus and striatum, S3 Fig). Hence, within Pdgfbret/ret mice,
the occurrence of vascular calcifications did not spatially correlate with the degree of pericyte
loss and BBB leakage (see overview in S1 Table).
Discussion
PFBC is an age-dependent neurological disease characterized by the formation of granular cal-
cifications in specific regions of brain parenchyma [16]. Since the first autopsy study in 1850
[31], strong evidence have accumulated that PFBC is primarily a vascular disease. Located
around the brain capillaries [32,33], most calcified nodules seem to form within the vascular
basement membrane, possibly nucleating in the pericytes [34]. The identification of familial
monogenic forms of PFBC resulting from mutations in PDGFB and PDGFRB strengthened the
link between PFBC and vasculature. However, the extent to which human mutations alter
PDGF-B signaling and impact pericyte recruitment, maintenance and function has remained
unclear. In the present study, we demonstrate that the six PDGFBmutations analyzed are all
null or loss-of-function alleles. We confirm that at least one of the PDGFRBmutation (L658P)
results in a complete, or nearly complete, loss of signaling capacity [18,21]. We also demon-
strate that, comparable degrees of genetic haploinsufficiency in mice did not cause brain calcifi-
cation, and moreover, that a more pronounced (90%) decrease in PDGF-Rβ protein level
also did not cause brain calcification. Somewhat surprisingly, these situations of limited
PDGF-Rβ signaling did also not cause significant decreases in pericyte coverage or impairment
of the BBB (see overview in S1 Table).
PDGFBmutations
PDGFB encodes a PDGF-B protein that makes up a biologically active PDGF-BB dimer
through disulfide bridging of cysteine residues 124 and 133 [35]. Heterozygous PDGFBmuta-
tions can impact PDGF-BB processing and function by abolishing protein synthesis or yielding
an inactive protein that does not interfere with wild-type PDGF-B processing. This would lead
to a theoretical 50% decrease in PDGF-BB through haploinsufficiency without compensatory
mechanisms. Indeed, doubly heterozygous Pdgfb+/-;Pdgfrb+/- mice lack compensatory upregu-
lation of mRNA from the intact alleles (Fig 7A). The recently described intragenic deletion
prior to sacrifice of the mice. The calcification prone regions of the brain were microdissected, and after homogenizing of the tissue, fluorescence was
measured and normalized over the tissue weight (AFU). The standard deviation of 4 animals per genotype is indicated by the error bars. *p<0,05 when
comparing Pdgfbret/ret with Pdgfbret/+, #p<0,05 when comparing calcification-prone regions with non-calcification-prone regions in Pdgfbret/ret mice.
doi:10.1371/journal.pone.0143407.g008
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involving 4 out of 6 exons in PDGFB probably leads to a pure haploinsufficiency [20]. The mis-
sense mutation in the signal peptide (L9R) probably functions as a heterozygous null as well,
because an N-terminal processing-deficient PDGF-B would fail to be translocated into the
endoplasmic reticulum for further processing and secretion.
However, an inactive PDGF-B, which retains the ability to dimerize is potentially domi-
nant-negative, and would be predicted to cause a 75% decrease in active PDGF-BB levels. The
nonsense mutations (Q145, Q147 and R149), which are all situated downstream of the cys-
teine residues engaged in inter-chain bridging (Fig 1A), could potentially retain the ability to
dimerize, as could the M1? and 242Yext89 mutant proteins. While an intracellular protein
product was only detectable for the two latter (Fig 2B), it remains possible that the former
mutations do yield a protein product that is either immediately degraded or not recognized by
the antibodies. Finally, the missense mutation in the receptor-binding loop (L119P) could hin-
der binding of the PDGF-B pro-peptide to the mature chain. The corresponding leucine in
PDGF-A (L118) was shown to be essential for correct protein folding and secretion [36]. Plac-
ing the PFBC PDGF-B mutations on a ribbon model of PDGF-B indeed suggests that L119
(green in Fig 1B) is located on the outer surface of the L1 loop (grey in Fig 1B), among a large
cluster of hydrophobic amino acids similar to L118 in PDGF-A chain.
Thus, Q145, Q147, R149 and L119P may all be unstable proteins that are rapidly targeted
for intracellular degradation. In contrast the M1? and 242Yext89 proteins accumulated intra-
cellularly at levels that were comparable to wild-type PDGF-B, but with abnormal sizes corre-
sponding to alternative translation initiation and C-terminal extension, respectively. A
PDGF-Rβ binding-based ELISA assay detected only the 242Yext89 product in conditioned
cell culture medium, suggesting that if any of the other mutant proteins are secreted, they fail
to accumulate to significant levels extracellularly. Finally, although the 242Yext89 product
bound to PDGFRβ epitopes in the ELISA assay, it failed to induce any detectable PDGF-Rβ
autophosphorylation or any of the cellular cytoskeletal rearrangements typical for wild-type
PDGF-BB. In conclusion, our analysis suggests that all PFBC mutations in PDGFB lead to loss
of a functional PDGF-B protein.
PDGFRBmutations
Regarding PDGFRBmutations, we confirm and complement recently reported data. In their
recent study, Sanchez-Contreras et al. [18], transfected HeLa cells with different PDGFRB-
expressing constructs, two carrying the L658P and R987Wmutations [14], and two carrying
two novel R695C and A1096V mutations identified in autopsy material stored in a brain bank
of sporadic PFBC patients [18]. While the A1096V mutant behaved like the wild-type and was
assumed to represent a benign variant, the L658P and R695C mutations resulted in defective
PDGFRβ autophosphorylation. The R987Wmutation led to decreased levels of protein [18].
We herein confirm the reported changes in L658P and R987W using two different cell types,
HEK and PAE cells, the latter of which allowed us to assess also relevant cellular responses to
PDGF-Rβ phosphorylation. PDGFRB-transfected PAE cells are a model of choice to study
PDGF receptor function because they lack endogenous PDGF receptors, but contain all the
necessary downstream effectors, and they respond similar to endogenously PDGF-Rβ-express-
ing fibroblasts by actin reorganization and chemotaxis upon PDGF-Rβ stimulation [26].
The L658P mutant lacked signaling ability, most likely because the new proline residue is
close to the ATP-binding pocket in a highly conserved region (Fig 1C and S4 Fig) [14]. For the
other two mutants, R987W and E1071V, our results are more ambiguous. We could reproduce
the slight decrease in protein levels of the R987Wmutant, as seen by Sanchez-Contreras et al.,
but the in vivo relevance of this decrease is less clear, as an animal model with extreme
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reduction in functional PDGF-Rβ expression (Pdgfrbredeye/redeye) has no detectable vessel-asso-
ciated calcifications (Fig 7). Alternatively, the R987Wmutated receptor is disease-causing
through its impaired signaling potential, as seen in the reduced activation of ERK1/2, AKT,
and especially PLCγ (Fig 5). Indeed, we observed reduced phosphorylation levels of residue
Y1009 in R987W (S2 Fig), which, together with Y1021, is necessary for PLCγ phosphorylation
and activation [37]. PDGF-BB is a potent and selective stimulator of inorganic phosphate
transport in vascular smooth muscle cells, an effect principally mediated by PLCγ [38]. This
possible link between PDGF-Rβ, PLCγ and phosphate transport deserves further investigation,
since mutations in the inorganic phosphate transporter Pit-2 (SLC20A2) [39], and the phos-
phate exporter XPR1 [40] are also linked to PFBC.
While R987W affects a phylogenetically conserved arginine residue in the C-terminal
domain, the E1071V mutation is situated in the phylogenetically variable C-terminus of
PDGF-Rβ (S4 Fig). In addition, its effect on downstream signaling is less pronounced than
R987W, suggesting that this mutation might represent a benign polymorphism. Interestingly,
although all three PDGFRBmutations displayed significantly less membrane ruffles when stim-
ulated with PDGF-BB, this did not translate into impaired migration of PAE cells expressing
R987W or E1071V PDGF-Rβmutants as measured in vitro in a scratch “wound healing” assay
(Fig 6). One possible explanation for this is that endothelial migration is regulated mostly
though ERK1/2 and Akt activity [38], and to a lesser extend through PLCγ activity.
How does impaired PDGF-B/ PDGF-Rβ signaling cause PFBC?
Our analysis establishes that mutations in PDGFB and PDGFRB associated with PFBC cause loss
or reduced formation or function of the gene product. However, it remains unclear how impaired
PDGF-B/PDGF-Rβ signaling causes brain calcification. The PDGFB and PDGFRBmutations
described so far are dominant heterozygous mutations. Homozygosity for the same mutations
may potentially cause pre- or perinatal lethality, similar to the situation in mouse homozygous
knockouts [5,6]. In contrast to the situation in humans, however, heterozygous mouse knockouts
of Pdgfb or Pdgfrb (not shown), and even the double heterozygotes Pdgfb+/-;Pdgfrb+/- mice, did
not develop brain calcifications (Fig 7). We reasoned that Pdgfb+/-;Pdgfrb+/- should mimic the
L658P mutation in the sense that both would be predicted to cause75% loss of signaling, in
Pdgfb+/-;Pdgfrb+/- mice due to the combined 50% reduction of PDGF-B and PDGFRβ levels, and
in the case of L658P, by an expected dominant-negative effect in receptor dimers. In a further
attempt to mimic the L658P mutation in mice we investigated Pdgfrbredeye/redeyemice, which dis-
play a 75% reduction of Pdgfrb transcript levels [30] and a 90% reduction in PDGF-Rβ protein
levels (Fig 7B). Intriguingly, also Pdgfrbredeye/redeyemice failed to develop brain calcifications.
Thus, our data suggest that humans and mice differ with regard to the threshold levels of
PDGF-B/PDGF-Rβ signaling required to protect against brain calcification. Although
PDGF-Rβ signaling levels have not been directly measured in Pdgfbret/ret and Pdgfb−/−;R26P+/0
mice, which develop brain calcifications [15], we conclude that it is likely lower compared to
Pdgfrbredeye/redeye and Pdgfb+/-;Pdgfrb+/- mice. This conclusion is based on analysis of brain ves-
sel coverage of pericytes, which is dependent on PDGF-B/PDGF-Rβ signaling. We previously
reported a correlation between the degree of pericyte deficiency in brain microvessels, BBB
impairment and the extent and onset age of brain calcification [15]. In our present analysis, we
found that the pericyte coverage was 70–80% in Pdgfb+/-;Pdgfrb+/- mice compared to wild-type
mice (Fig 8B), a ratio comparable to the previously analyzed Pdgfb−/−;R26P+/+ mice (72% peri-
cyte coverage compared to normal), which also lack brain calcifications [41]. Somewhat sur-
prisingly, Pdgfrbredeye/redeye mice did not display any measurable reduction in pericyte coverage
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despite a 90% reduction of PDGF-Rβ protein levels. This may suggest that in mice, PDGF-B
levels are more critically limiting for pericyte recruitment than PDGF-Rβ levels.
Taken together, these results show that in mice, more severely reduced levels of PDGF-B/
PDGF-Rβ signaling are required in order to trigger brain calcifications than in humans. It is
possible that the same holds true for pericyte and BBB deficiency. Histopathological signs of
BBB defects have been reported in one PFBC case [33], but until now, pericyte densities have
not been assessed in human PFBC cases. Thus, it remains unclear if pericyte loss and BBB
defects correlate with brain calcification also in human PFBC.
While our results further strengthen the correlation between brain calcification, and defective
PDGF-B/PDGF-Rβ signaling, pericyte loss and BBB impairment at a global level, we paradoxi-
cally did get opposite results when we analyzed the specific anatomical regions in Pdgfbret/retmice
that develop brain calcifications in comparison with regions that do not. Here, we found that the
calcification-prone regions had higher pericyte coverage and lower degree of BBB leakage than
calcification-non-prone regions. Whereas these data do not rule out a role for pericyte loss and
BBB impairment in brain calcification, it shows that these changes by themselves are not suffi-
cient to cause microvascular calcification in any brain region, but that other region-specific factor
(s) must also be involved. In this context it is interesting to note that the deep brain regions, such
as the basal ganglia in humans, appear particularly sensitive to develop calcifications in conjunc-
tion with systemic mineral imbalance or aging in humans [16,42,43]. Current mouse models of
PFBC also do not distinguish between the developmental role and a putative homeostatic func-
tion of PDGF-B signaling the brain vasculature. For example, it is possible that impaired
PDGF-B/PDGF-Rβ signaling accelerates an age-dependent phenotypic change in pericytes that
ultimately provokes the formation of microvascular calcification. Senescence and damage to vas-
cular smooth muscle cells has been shown to cause vascular calcification of peripheral vessels
[44]. These and other questions should be possible to address using inducible Pdgfb and Pdgfrb
ablation as well as by crossing current models of PFBC, such as Pdgfbret/ret, into different sensi-
tized or protective genetic backgrounds, and by exposing them to different systemic challenges,
such as the induction of mineral imbalances.
Material and Methods
Generation of cDNA constructs carrying the PFBCmutations
Generation of cDNA constructs carrying the PFBC PDGFBmutations Human PDGFB tran-
script variant 1 cDNA (NM_002608.2) was bought from GeneCopoeia and subcloned into a
pcDNA3.1 vector (Life Technologies). This construct contains the coding sequence for
PDGF-B, as well as 255 bp upstream and 1105 bp downstream of the cDNA. To generate the
L119P, Q145 and R149 PDGFBmutants, a QuickChange II Site-Directed Mutagenesis Kit
(Agilent Technologies) was used. Primers were as follows: forward primer 5'-ACG CCA ACT
TCC CGG TGT GGC CGC C-3' and reverse primer 5'-GGC GGC CAC ACC GGG AAG TTG
GCG T-3' to generate L119P; forward primer 5'-GCC GCC CCA CCT AGG TGC AGC TG-3'
and reverse primer 5'-CAG CTG CAC CTA GGT GGG GCG GC-3' to generate Q145; for-
ward primer 5'-CCA GGT GCA GCT GTG ACC TGT CCA GGT-3' and reverse primer 5'-
ACC TGG ACA GGT CAC AGC TGC ACC TGG-3' to generate R149. The remaining four
mutations, namely M1?, L9R, Q147 and 242Yext89, were generated in the original
pcDNA3.1 PDGFB construct by GenScript (GenScript USA Inc). All constructs were verified
by sequencing.
Constructs of human wild-type and kinase-dead (KD) PDGFRB cDNA subcloned into the
pcDNA3.1 vector (Life Technologies) were described previously [26]. The KD construct bore
the K634A mutation in which the nucleotide-binding lysine of the protein-tyrosine domain
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has been changed to alanine [26]. To generate the three PDGFRBmutants, namely L658P,
R987W and E1071V, a QuikChange II Site-Directed Mutagenesis Kit was used. Primers were
as follows: forward primer 5'-GAT CAT GAG TCA CCC TGG GCC CCA CCT GA-3' and
reverse primer 5'-TCA GGT GGG GCC CAG GGT GAC TCA TGA TC-3' to generate L658P;
forward primer 5'-CCA CCC AGC CAT CCT TTG GTC CCA GG-3' and reverse primer 5'-
CCT GGG ACC AAA GGA TGG CTG GGT GG-3' to generate R987W; forward primer 5'-
CAG GAC GAA CCA GTG CCA GAG CCC CAG-3' and reverse primer 5'-CTG GGG CTC
TGG CAC TGG TTC GTC CTG-3' to generate E1071V. All constructs were verified by
sequencing.
Cell culture and transfection
Human embryonic kidney (HEK293) cells were purchased from ATCC and cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum,
2 mM L-glutamine, 10 U/ml penicillin, and 10 μg/ml streptomycin. Porcine Aortic Endothelial
(PAE) cells [45] were cultured in DMEM and Ham’s F12 nutrient mixture (DMEM:F12) sup-
plemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 10 U/ml penicillin, and
10 μg/ml streptomycin. Human brain vascular pericytes (HBPs) were purchased from Scien-
Cell and cultured under standard culture conditions according to the manufacturer’s protocol.
cDNA vectors were introduced into the cells by Lipofectamine Plus transfection (Life Tech-
nologies). Cells were transfected at 70% confluency with 2.5 μg of DNA, 7 μl of Lipofectamine,
2.5 μl of Plus reagent and 200 μL OptiMEM (Life Technologies) per well in a 6-well plate. One
day after transfection, the medium was removed and replaced by selection medium (normal
growth medium with G418 sulfate 500 μg/ml, Life Technologies). To generate stable polyclonal
colonies, cells were then kept in the selection medium and cultured at least three passages
before use.
RT-PCR and ELISA
Total RNA was extracted from HEK293 or PAE cells and DNase-treated using the RNeasy
Mini kit (Qiagen). Total RNA was extracted for mouse brains and DNase-treated using the
RNeasy Lipid Tissue Mini kit (Qiagen). cDNA was synthetized using the iScript™ cDNA Syn-
thesis Kit (Bio-Rad). Real-time quantitative PCR was performed on a CFX96 Touch RT-PCR
machine (Bio-Rad) using either SYBRgreen (iTaq Universal SYBR Green Supermix, Bio-Rad)
or TaqMan probes (Life Technologies). In all conditions, eukaryotic 18S rRNA (4319413E)
was used as a reference gene for ΔΔCt calculations. Since HEK293 cells express detectable levels
of human PDGFB mRNA, their expression level was taken as 1 and the other values are
expressed as fold increase over basal expression. When using SYBRgreen, the following primers
were used. For detection of human PDGFB: forward primer 5’-GAT GAT CTC CAA CGC
CTG-3’ and reverse primer 5’-TCC TTC TTC CAC GAG CCA-3’. For detection of human
PDGFRB: forward primer 5’-ACC TGC AAT GTG ACG GAG GAG-3’ and reverse primer 5’-
AAC ACT ACC TGC AGT GTC CG-3’. The following TaqMan probes were used: Mouse
Pdgfrb (Mm00435546_m1) and mouse Pdgfb (Mm00440677_m1). All RT-PCR data is repre-
sented as the mean of three independent experiments.
The Quantikine ELISA Kit (R&D Systems) was used to measure the concentration of
PDGF-BB in the conditioned media.
PDGF-BB stimulation andWestern blotting
Conditioned medium was prepared from serum-starved HEK293 cell transfected either with
an empty-vector or with vectors encoding wild-type or mutant PDGFB. After 24 hours
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medium was collected, centrifuged and the supernatant was stored at -80°C until further use.
Recombinant human PDGF-BB was purchased from R&D Systems. For PDGFRβ autopho-
sphorylation assays, cells were starved in serum-free medium overnight and cooled on ice for
15 min before addition of 40 ng/ml PDGF-BB, conditioned medium collected from HEK cells
transfected with plasmids encoding wild-type or mutant PDGF-Bs, or PDGF-BB dilution
buffer only. Cells were kept on ice for 1 hour before lysis. For time-course analysis, PDGF-BB
was directly added to the normal growth medium at 37°C to reach a concentration of 40 ng/ml.
Cells were rinsed with ice-cold PBS and snap-frozen at different time-points. All cells were
lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxy-
cholate, 0.1% SDS) containing 2 mM orthovanadate and protease inhibitors (Complete; Roche
Molecular Biochemicals).
Unless stated otherwise, equal protein amounts from whole-cell extract were subjected to
SDS/PAGE electrophoresis and electrotransferred to a PVDF membrane (Bio-Rad). Protein
concentrations were determined using the BCA method (Thermo Scientific, Pierce). Proteins
were visualized by incubating membranes with specific antibodies: rabbit monoclonal anti-
PDGF-Rβ (28E1, Cell Signaling Technology); rabbit monoclonal anti-phospho-PDGF-Rβ
(Y751), phospho-PDGF-Rβ (Y771), phospho-PDGF-Rβ (Y1009) and phospho-PDGF-Rβ (Tyr
1021) (Cell Signaling Technologies); rabbit monoclonal anti-phospho-p44/42 MAPK (ERK1/
2) (Thr202/Tyr204) (Cell Signaling Technologies); rabbit polyclonal anti-phospho-Akt
(Ser473) (Cell Signaling Technologies); rabbit anti-phospho-PLCγ1 (Tyr783) (Cell Signaling
Technologies); rabbit anti-PDGF-BB antibody (AbCam). After incubation with an HRP-cou-
pled secondary antibody, the membrane was soaked in a chemiluminescent substrate (Clarity
Western ECL substrate, Bio-Rad). A high-resolution CCD camera (ChemiDoc MP, Bio-Rad)
was used for signal detection and optimal exposure was determined by the software. Band
intensities were analyzed by densitometry using Image Lab software (Bio-Rad).
For the autophosphorylation study, the amount of PDGF-Rβ was first determined in cell
lysates by Western blotting. Lysates were then diluted to yield a comparable amount of
PDGF-Rβ signal in each condition. The ratio of phospho/total PDGF-Rβ signal was calculated
for each analyzed tyrosine residue and expressed as a percentage of the ‘wild-type PDGF-Rβ,
PDGF-BB-treated’ condition, which was arbitrarily set to 100% in each individual experiment.
Deviation from this value was analyzed with one-sample t-tests (mean = 100; two-tailed). For
the downstream signaling study, the ratio to β-actin signal was calculated for each pathway and
expressed as a percentage of the condition in which wild-type PDGF-Rβ was treated with
PDGF-BB for 5 minutes, which was arbitrarily set to 100% in each individual experiment.
Deviation from this value at 5 minutes was analyzed with one-sample t-tests (mean = 100; two-
tailed). Deviation from wild-type PDGF-Rβ at other time points was analyzed using one-way
ANOVAs followed by Dunnett’s multiple comparison tests.
Western blotting on mouse brain lysates was performed using the same method. One brain
hemisphere per mouse was used for protein extraction. Homogenization was performed in
RIPA buffer completed with protease and phosphatase inhibitors. Protein concentrations were
determined in the supernatant using a BCA assay and normalized by dilution in RIPA. Ten μg
total protein were loaded in each well.
PDGF-BB-induced actin reorganization and in vitro scratch wound
assays
To assess PDGF-BB-induced actin reorganization in PAE cells and HBPs, 5 x 104 cells were
seeded in glass-bottom 24 well-plates and cultured overnight. Subsequently, the cells were
serum-starved overnight, cooled on ice for 15 min, and medium was replaced by either
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conditioned medium or fresh medium containing PDGF-BB. After a 30-min incubation on ice,
cells were transferred back to the 37°C incubator for 15 min, then washed in phosphate-buff-
ered saline (PBS) and fixed in 3.75% formaldehyde/PBS. Phalloidin staining was performed by
incubating the cells in 3% bovine serum albumin (BSA) - 0.5% Triton X-100 /PBS for 1 hour,
then in 2.5% PromoFluor 488-phalloidin (PromoKine) - 0.01% Hoechst 33342 (Life Technolo-
gies) - 1% BSA/PBS for 30 min. Cells were post-fixed for 2 min in 3.75% formaldehyde before
mounting. Pictures were taken with a Leica TCS SP8 confocal microscope (Leica Microsys-
tems) using a 63x objective (N/A 1.40). For quantification of membrane ruffles in PAE cells, 1
stitched image consisting of 9 adjacent images (3x3) was taken per condition (at 20x magnifica-
tion, N/A 0.8). Ruffles were manually counted and the total ruffle count was normalized over
the total amount of cells in the image. The latter were counted automatically using Fiji [46]. All
images were deconvolved prior to analysis and presentation (AutoQuant X3,
MediaCybernetics).
In vitro scratch wound assays were performed on stably transfected PAE cells grown until
confluence in 96-well ImageLock Microplates (Essen Bioscience). After a 2 hour-starvation
in serum-free medium, a single wound was made down the center of each well using the
96-well WoundMaker (Essen Bioscience). Cells were washed in PBS and then stimulated
with 40 ng/ml PDGF-BB or vehicle. Wound images were then automatically acquired and
registered -by the IncuCyte Zoom live-cell imager (Essen Bioscience) for every 2h until the
wound was healed. Data were then analyzed in relative wound density/time. Relative wound
density measures the spatial cell density in the wound area relative to the spatial cell density
outside of the wound area at every time point. It is designed to be 0% at t = 0, and 100% when
the cell density inside the wound is the same as the cell density outside the initial wound.
This metric is calculated by custom algorithms, which are part of the IncuCyte software pack-
age (Essen BioScience).
Animals and animal experiments
Pdgfb and Pdgfrb knockout mice [5,6] were bred to generate double heterozygous mice
(Pdgfb+/-;Pdgfrb+/-). Pdgfrbredeye/+ mice were obtained from the Medical Research Council
(MRC), UK. Mouse Contract Services were provided by the Marie Lyon Centre at MRC Har-
well (www.har.mrc.ac.uk). Pdgfbret/ret mice have been described previously [41,47]. This
study was carried out in strict accordance to the recommendations of the Swedish Ethical
Committee on Animal Research. The protocol was approved by the Stockholm North Ethical
Committee on Animal Research (Permit number N16/12) and by the Uppsala Ethical Com-
mittee on Animal Research (Permit number: C224/12 and C225/12). All surgery was per-
formed under terminal anesthesia, and all efforts were made to minimize suffering.
For blood-brain barrier integrity assessment, lysine-fixable cadaverine (25 μg/g body
weight) conjugated to Alexa Fluor-555 (Life Technologies) was injected intravenously into the
tail vein 2 hours before sacrifice. Anaesthetized animals were perfused transcardially for 5 min
with Hanks’ balanced salt solution (HBSS). Half of the forebrain and one kidney were removed
and homogenized in 1% Triton X-100 /PBS, pH 7.2. Brain and kidney lysates were centrifuged
at 14,000 rpm for 20 min and the relative fluorescence of the supernatant was measured using
a Synergy HT microplate reader (BioTek) with the following settings: excitation: 540/25 nm,
emission: 590/20 nm. To assess regional differences in the blood-brain barrier permeability,
different brain regions were dissected under a stereomicroscope and weighed prior to homoge-
nization, then processed the same way as half-brains. Kidneys were used as a control to ensure
the systemic distribution of the injected tracers. Results were expressed as arbitrary fluorescent
units normalized to the tissue weight (AFU/g).
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For immunohistochemical studies, fifty μm sagittal vibratome sections of the mouse brains
were successively incubated in blocking/permeabilization solution (1% bovine serum albumin,
0.5% TritonX-100 in PBS), primary antibody solution, and secondary antibody solution for 20
hours at 4°C. Sections were mounted in Prolong Gold antifade reagent (Life Technologies).
The following primary antibodies were used: goat anti-mouse CD31 (R&D Systems); rat anti-
mouse CD13 (AbD Serotec). Specimens were analyzed using a Leica TCS SP8 confocal micro-
scope (Leica Microsystems). All immunohistochemistry images presented are 2D maximum
intensity projections of ~40 μm z-stacks.
Pericyte coverage was estimated using a self-designed Fiji macro [46]. The estimation of
capillary ensheathment by pericytes was performed by quantifying the ratio of CD31-positive
area (in green) overlapped by CD13 (in red) in maximal intensity projections of the Z-stack.
After transforming each layer into binary images using Tsai’s AutoThreshold function [48],
layers were merged back and the ratio of yellow (colocalized) over yellow and green (CD31)
pixels was calculated for each image. In each experiment, 4 animals per group were studied,
and 2 images were acquired per animal for each region. Pericyte-coverage was determined in
cortex and dorsal pons in Pdgfb+/-;Pdgfrb+/- and Pdgfrbredeye/redeye mice and littermate controls,
and in cortex, hippocampus, myelencephalon, thalamus, mesencephalon and dorsal pons in
Pdgfbret/ret mice and littermate controls.
Micro-CT scanning and histochemistry methods have been described previously [15]. In
short, paraformaldehyde fixed whole-brain samples were incubated in iopromide (Ultravist
300, Bayer) to increase soft-tissue contrast. High-resolution data sets were obtained with a Sky-
scan 1176 small animal CT imager applying 50 kV tube voltage, 500mA tube current, an isotro-
pic voxel size of 18 μm, and a 0.5mm aluminium filter. Image reconstruction was performed
with a modified Feldkamp algorithm.
Statistical analysis
Unless stated otherwise, statistical significance was determined by using unpaired two-tailed
Student’s t-test For all statistical tests, p<0.05 was deemed significant. In graphs, error bars
represent the SD from independent experiments; , #: p<0.05.
Supporting Information
S1 Fig. Conditioned medium from mutant PDGFB-transfected HEK cells fails to induce
membrane ruffles in human brain pericytes.Overview demonstrating that the supernatant of
mutant PDGF-B producing HEK293 cells does not induce circular ruffles in HBP cells. In addi-
tion, additional positive controls with exogenous PDGF-BB (40 ng and 100 ng per ml) are
shown. Cyan: DAPI. Green: Alexa 488 conjugated phalloidin. Scale bar: 30 μm. Arrowheads
point at representative ruffles.
(TIF)
S2 Fig. Quantification of PDGF-Rβ autophosphorylation signal from tyrosine residues
751, 771, 1009 and 1021 using phospho-specific antibodies. Signals were normalized over
total levels of PDGF-Rβ protein, then expressed as a percentage of wild-type PDGF-Rβ autop-
hosphorylation. Shown in the graphs are the results from the 4 tyrosine residues that were
assessed in three independent experiments. p<0,05 when compared to the positive control
(wild-type PDGF-Rβ).
(TIF)
S3 Fig. Comparison of pericyte coverage and blood-brain barrier integrity between calcifi-
cation-prone and non-calcification-prone regions in pdgfbret/retmice. (A) Pericyte coverage
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in different brain regions in pdgfbret/ret mice. The data is plotted as the percentage of the vessel
surface enveloped by pericytes. For each brain region, four pictures were analyzed. The stan-
dard deviation of pericyte coverage of 4 animals per genotype is indicated by the error bars.
p<0,05 when comparing Pdgfbret/ret regions with the corresponding Pdgfbret/+ regions. (B)
Blood-brain barrier integrity in different brain regions in pdgfbret/ret mice. Fluorescent tracer
was allowed to circulate for 2 hours prior to sacrifice of the mice. The different brain regions
were micro-dissected, and after homogenizing of the tissue, fluorescence was measured and
normalized over the tissue weight. The 3 calcification prone regions are grouped on the left of
the graph. p<0,05 when comparing Pdgfbret/ret regions with the corresponding Pdgfbret/+
regions.
(TIF)
S4 Fig. Amino acid sequence alignment of PDGFRB between orthologues. The human
sequence of PDGF-Rβ was aligned toMacaca fascicularis (rhesus monkey), Rattus norvegicus
(common rat),Mus musculus (house mouse) and Gallus gallus (red junglefowl). While L658P
and R987W are highly conserved, E1071 is only conserved between Homo sapiens andMacaca
fascicularis.
(TIF)
S1 Movie. Time lapse imaging of wound closure of PAE cells expressing wild-type
PDGF-Rβ and PDGF-Rβ L658P. The cells were imaged every hour for 13 hours to record
wound healing. While wild-type PDGF-Rβ expressing cells were able to close the wound in the
allotted time frame, the PDGF-Rβ L658P expressing cells failed to do so.
(MP4)
S1 Table. Overview of the findings.
(DOCX)
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